Clinical trials: Relapsed/ Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination…
- Trial name
- NCT06655818
- Testing
- Belantamab Mafodotin, Dostarlimab
- Where
- 3 sites in France, South Korea
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with…
- Trial name
- NCT01456689
- Testing
- LGH447, midazolam
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, Plasma Cell Leukemia
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe…
- Trial name
- NCT06045091
- Testing
- Human BCMA targeted CAR-NK cells injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of Human Derived anti-BCMA CAR-T Injection , and to preliminarily observe the…
- Trial name
- NCT05302648
- Testing
- Human Derived anti-BCMA CAR-T Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
- Trial name
- QUINTESSENTIAL (NCT06297226)
- Testing
- Arlocabtagene Autoleucel
- Where
- 52 sites in United States, Australia and 2 more
- Volunteers
- 230 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies.
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
- Trial name
- ADAPT-HEM (NCT07523555)
- Testing
- Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Beijing Biotech
Multiple Myeloma
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified in NCT03399799 study.
- Trial name
- NCT04773522
- Testing
- Talquetamab
- Where
- 6 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
The main aim is to show that long-term use of ixazomib can improve symptoms of multiple myeloma and provide an effective long-term alternative treatment.
- Trial name
- US MM-7 (NCT05183139)
- Testing
- Ixazomib, Pomalidomide, Lenalidomide
- Sponsor
- Takeda
Multiple Myeloma Refractory
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
The goal of this clinical trial is to learn if the antibody drug HuL001, combined with Lenalidomide/Dexamethasone works to treat Multiple Myeloma patients.
- Trial name
- NCT07210047
- Testing
- HuL001, Lenalidomide/Dexamethasone
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- HuniLife Biotechnology, Inc.
Plasma Cell Myeloma
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma
Primary Objective: Part A: To evaluate the safety of SAR650984 (isatuximab) in patients with relapsed/refractory multiple myeloma (RRMM).
- Trial name
- NCT02514668
- Testing
- Isatuximab
- Where
- 18 sites in United States, Czechia and 1 more
- Volunteers
- 55 people
- Sponsor
- Sanofi
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
This trial is a multi-center, single-arm phase 2 study to evaluate the efficacy and safety of TJ202 combined with dexamethasone in subjects with relapsed or refractory multiple myeloma (RRMM) who received at least 2 prior lines…
- Trial name
- NCT03860038
- Testing
- TJ202 and Dexamethasone
- Where
- 18 sites in China, Taiwan
- Volunteers
- 113 people
- Sponsor
- TJ Biopharma Co., Ltd.
Multiple Myeloma
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to assess the safety of the combination of JNJ-63723283 and daratumumab (Part 1); to compare the overall response rate (ORR) in participants treated with JNJ-63723283 in combination with…
- Trial name
- NCT03357952
- Testing
- Daratumumab, JNJ-63723283
- Where
- 13 sites in Belgium, Israel and 1 more
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
This is a Phase 2 open-label study to evaluate the efficacy and safety of ibrutinib in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory multiple myeloma.
- Trial name
- NCT02902965
- Testing
- Ibrutinib, Bortezomib, Dexamethasone
- Where
- 33 sites in Czechia, Germany and 4 more
- Volunteers
- 74 people
- Sponsor
- Pharmacyclics Switzerland GmbH
Plasma Cell Myeloma
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Primary Objective: To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months To assess other effectiveness parameters such as progression…
- Trial name
- IONA-MM (NCT04458831)
- Testing
- isatuximab SAR650984, Pomalidomide, Dexamethasone
- Where
- 129 sites in United States, Argentina and 19 more
- Volunteers
- 583 people
- Sponsor
- Sanofi
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore…
- Trial name
- NCT07217119
- Testing
- Belantamab mafodotin, Feladilimab
- Where
- 11 sites in United States, Australia and 6 more
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
NHL, Multiple Myeloma
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without…
- Conditions
- NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
- Trial name
- NCT06119685
- Testing
- IDP-023, Rituximab, Daratumumab
- Where
- 12 sites in United States
- Volunteers
- 128 people
- Sponsor
- Indapta Therapeutics, INC.
Multiple Myeloma
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
This study will be available to any participant who has received or is currently receiving belantamab mafodotin treatment through either a clinical trial, an access program, or a physician prescription.
- Trial name
- NCT04549363
- Testing
- Belantamab mafodotin
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
The main objectives are to evaluate the safety and tolerability of AMG 176 monotherapy in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT02675452
- Testing
- AMG 176, Azacitidine, Itraconazole
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 141 people
- Sponsor
- Amgen
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT04398485
- Testing
- ION251
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Multiple Myeloma, Plasma Cell Disorder
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
- Trial name
- NCT04879043
- Testing
- HDP-101
- Where
- 24 sites in United States, Germany and 3 more
- Volunteers
- 78 people
- Sponsor
- Heidelberg Pharma AG